Analysts expect Collegium Pharmaceutical Inc (NASDAQ:COLL) to report earnings per share of ($0.15) for the current fiscal quarter, Zacks reports. Six analysts have provided estimates for Collegium Pharmaceutical’s earnings. The highest EPS estimate is ($0.03) and the lowest is ($0.21). Collegium Pharmaceutical reported earnings of ($0.10) per share in the same quarter last year, which would indicate a negative year over year growth rate of 50%. The business is expected to announce its next earnings results on Wednesday, February 26th.
According to Zacks, analysts expect that Collegium Pharmaceutical will report full year earnings of ($0.64) per share for the current financial year, with EPS estimates ranging from ($0.82) to ($0.25). For the next financial year, analysts forecast that the firm will report earnings of $0.19 per share, with EPS estimates ranging from ($0.31) to $0.94. Zacks’ earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Collegium Pharmaceutical.
Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Wednesday, November 6th. The specialty pharmaceutical company reported ($0.18) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.03). Collegium Pharmaceutical had a negative net margin of 3.86% and a negative return on equity of 13.14%. The business had revenue of $72.94 million during the quarter, compared to analyst estimates of $74.32 million. During the same quarter last year, the company posted ($0.50) earnings per share. The company’s revenue was up 3.9% on a year-over-year basis.
Several equities research analysts recently weighed in on the stock. Needham & Company LLC cut their price objective on shares of Collegium Pharmaceutical from $33.00 to $25.00 and set a “buy” rating for the company in a research report on Wednesday, October 30th. SunTrust Banks upped their price objective on shares of Collegium Pharmaceutical to $22.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Zacks Investment Research cut shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Thursday, November 7th. BidaskClub raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Wednesday, November 6th. Finally, Jefferies Financial Group upped their price objective on shares of Collegium Pharmaceutical from $26.00 to $36.00 in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating and eight have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $24.57.
COLL traded down $0.18 on Friday, hitting $18.11. 410,300 shares of the stock were exchanged, compared to its average volume of 380,659. Collegium Pharmaceutical has a 12 month low of $10.01 and a 12 month high of $19.99. The business has a 50-day moving average of $12.93 and a two-hundred day moving average of $12.20. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.24 and a quick ratio of 1.20. The firm has a market capitalization of $641.71 million, a price-to-earnings ratio of -15.21 and a beta of 0.52.
In other news, Director David Hirsch sold 25,000 shares of the stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $19.33, for a total value of $483,250.00. Following the completion of the transaction, the director now owns 17,117 shares of the company’s stock, valued at $330,871.61. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Joseph Ciaffoni sold 64,821 shares of the stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $18.77, for a total transaction of $1,216,690.17. Following the completion of the transaction, the chief executive officer now directly owns 242,276 shares of the company’s stock, valued at approximately $4,547,520.52. The disclosure for this sale can be found here. Insiders sold 111,927 shares of company stock valued at $1,957,475 in the last three months. Company insiders own 8.08% of the company’s stock.
Several hedge funds have recently bought and sold shares of COLL. Cortina Asset Management LLC lifted its holdings in shares of Collegium Pharmaceutical by 81.0% in the second quarter. Cortina Asset Management LLC now owns 509,701 shares of the specialty pharmaceutical company’s stock worth $6,703,000 after acquiring an additional 228,035 shares during the last quarter. First Quadrant L P CA lifted its holdings in shares of Collegium Pharmaceutical by 87.2% in the second quarter. First Quadrant L P CA now owns 4,484 shares of the specialty pharmaceutical company’s stock worth $59,000 after acquiring an additional 2,089 shares during the last quarter. Strs Ohio raised its holdings in Collegium Pharmaceutical by 24.9% in the 2nd quarter. Strs Ohio now owns 49,700 shares of the specialty pharmaceutical company’s stock valued at $653,000 after buying an additional 9,900 shares during the last quarter. Janus Henderson Group PLC raised its holdings in Collegium Pharmaceutical by 19.1% in the 2nd quarter. Janus Henderson Group PLC now owns 4,323,555 shares of the specialty pharmaceutical company’s stock valued at $56,855,000 after buying an additional 693,812 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale raised its holdings in Collegium Pharmaceutical by 63.6% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 21,600 shares of the specialty pharmaceutical company’s stock valued at $286,000 after buying an additional 8,400 shares during the last quarter. 91.02% of the stock is owned by hedge funds and other institutional investors.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.
Read More: What is the G-20?
Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Collegium Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Collegium Pharmaceutical and related companies with MarketBeat.com’s FREE daily email newsletter.
